Verteporfin Photodynamic Corneal Cross-Linking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional corneal cross-linking methods, such as the Dresden protocol using riboflavin and UVA light, face limitations in treating thin corneas due to the risk of endothelial damage and side effects like stromal haze and microbial keratitis, necessitating a safer and more effective method to increase corneal rigidity.
Innovation Solution
The use of non-thermal photodynamic therapy with verteporfin, where verteporfin is topically administered to the cornea and activated with non-thermal laser light to induce collagen cross-linking, enhancing corneal biomechanical strength without the risks associated with UVA exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If conventional CXL uses riboflavin and UVA light to increase corneal stiffness, then corneal rigidity is improved, but endothelial damage and side effects occur
Solution Approach 1:
The patent changes the fundamental parameters of the cross-linking method by replacing riboflavin with verteporfin as the photosensitizer and substituting UVA light with red laser light (689 nm wavelength). This parameter change allows the treatment to achieve corneal cross-linking while avoiding the harmful effects of UVA radiation on the corneal endothelium, thus resolving the contradiction between improving corneal rigidity and preventing endothelial damage
Solution Approach 2:
The patent introduces verteporfin as an intermediary photosensitizer that can be activated by red laser light instead of requiring UVA activation like riboflavin. This intermediary substance enables the cross-linking reaction to proceed with a different light source that does not damage the endothelium, effectively mediating between the need for cross-linking and the need to protect endothelial cells
2Productivity
If UVA irradiance is increased to treat thinner corneas, then treatment efficacy is improved, but risk of endothelial damage increases
Solution Approach 1:
The patent changes the wavelength parameter of the light source from UVA (365 nm) to red laser light (689 nm), which has better tissue penetration and does not carry the same risk of endothelial damage. This allows effective treatment of thinner corneas without increasing the risk of harmful effects, as the red light can penetrate to the required depth without the damaging side effects of UVA
3Reliability
If riboflavin concentration and UVA exposure are optimized to minimize cell death, then safety is improved, but treatment duration and complexity increase
Solution Approach 1:
The patent simplifies the treatment protocol by changing the photosensitizer to verteporfin, which has a longer absorption peak at 689 nm that matches the red laser wavelength. This eliminates the need for repeated riboflavin instillation every 3-5 minutes during treatment, as verteporfin can be applied once and remains effective throughout the procedure, thereby reducing treatment complexity while maintaining safety
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively increases corneal rigidity, as demonstrated by enhanced resistance to enzymatic digestion and biomechanical testing, similar to traditional cross-linking methods but with reduced risk of endothelial damage, allowing treatment of thinner corneas and potentially reducing post-operative ectasia.
Implementation Method 1
photodynamic therapy with the photosensitizing compound verteporfin
Implementation Method 2
Photoactivation of riboflavin induces the formation of free radicals that interact with corneal proteins leading to covalent bonding within collagen fibrils
Data Source
AI summary
Described are compositions and methods of using verteporfin-based photodynamic therapy (PDT) to increase the biomechanical strength of the cornea. More particularly, described herein are compositions and methods for cross-linking collagen in corneal tissue which are useful in the treatment of corneal ectatic disorders.